Alectinib: A Game-Changer Beyond Lung Cancer – What's Next?

Alectinib, sold under the brand name Alecensa, is a powerful targeted therapy initially approved for treating ALK-positive non-small cell lung cancer (NSCLC). Since the groundbreaking ALINA trial in 2023, its role has expanded dramatically, showing promise in other ALK-driven cancers.

This article breaks down the latest breakthroughs, ongoing clinical trials, and how patients can determine if Alectinib is the right treatment.

The ALINA Trial: Hope for Early-Stage ALK-Positive NSCLC Patients

The Phase III ALINA trial was a game-changer, testing Alectinib as an adjuvant (post-surgery) treatment for early-stage ALK-positive NSCLC (stages IB-IIIA). Previously, patients relied on chemotherapy, but recurrence rates remained stubbornly high. ALINA set out to change that.

Key takeaways: Alectinib cut the risk of recurrence or death by 76% compared to chemotherapy. The medication also significantly lowered brain metastasis risk — a common concern for ALK-positive patients — and fewer patients discontinued treatment due to severe side effects versus chemotherapy. Common side effects include fatigue, constipation, and liver enzyme changes, though these are often manageable with medical support.

These results led to FDA approval in April 2024, making alectinib the new standard for preventing relapse in surgically removed (resected) ALK-positive NSCLC.

Beyond NSCLC: Alectinib for Patients with Other ALK-Driven Cancers

While NSCLC remains alectinib's primary focus, researchers are now testing it in other ALK-driven cancers, where early results are promising.

ALK-Positive Anaplastic Large Cell Lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma with ALK gene mutations. Other ALK inhibitors have worked well in ALCL, and early trials suggest Alectinib could be a safer, effective option.

ALK-Mutated Neuroblastoma is a pediatric cancer that affects the nervous system, with some cases driven by ALK mutations. Preclinical research shows that Alectinib can stop ALK-driven neuroblastoma growth, and trials are now underway for relapsed cases.

Inflammatory Myofibroblastic Tumors (IMTs) are a rare, aggressive tumor often driven by ALK gene fusions. Case reports show tumor shrinkage in some IMT patients, and trials are investigating its broader potential.

Clinical Trials: New Options for Lung Cancer, Lymphoma, Neuroblastoma, and IMT Patients

Since 2023, several new clinical trials have been launched to explore Alectinib's potential across different cancers.

For ALK-positive lung cancer (NSCLC): the NAUTIKA1 trial is testing alectinib before surgery (neoadjuvant) to shrink tumors and improve surgical outcomes; the ALNEO trial is similarly evaluating how pre-surgery alectinib affects tumor size and long-term survival; and the HORIZON-01 trial is investigating whether alectinib can prevent post-surgical recurrence better than chemotherapy.

For other ALK-driven cancers (lymphoma, neuroblastoma, IMTs): the ALKALINE trial is studying alectinib in ALK-positive pediatric cancers, specifically neuroblastoma, to see if it can help children with relapsed disease; and the IMT-ALK trial is evaluating alectinib's ability to shrink ALK-positive inflammatory myofibroblastic tumors in patients with this rare cancer.

The Future of Alectinib: What's Next for ALK-Driven Cancer Patients?

Alectinib has already reshaped ALK-positive lung cancer treatment, but its future looks even more promising. With earlier treatment opportunities, expanding cancer types, and ongoing research, more patients than ever may benefit from this breakthrough drug.

If you're wondering whether Alectinib is right for you, genetic testing and expert opinions are crucial next steps. Connecting with leading cancer centers and specialists like Dr. Elisha Fredman, an expert in ALK-driven cancers who can answer patient questions about clinical trials, is a great place to start. With new trials actively recruiting, now is the time to explore how Alectinib can offer hope for ALK-driven cancer patients worldwide.

Questions or corrections? Reach out to Moshe Melamed at melamed.moshemmd@gmail.com.